<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02611492</url>
  </required_header>
  <id_info>
    <org_study_id>AOM12629_1</org_study_id>
    <nct_id>NCT02611492</nct_id>
  </id_info>
  <brief_title>A Phase III Randomized Trial of the Reduction of Chemotherapy in Philadelphia Chromosome-positive ALL of Young Adults</brief_title>
  <acronym>GRAAPH2014</acronym>
  <official_title>A Phase III Study, Randomized, to Evaluate the Reduction of Chemotherapy Intensity in Association With Nilotinib (Tasigna®) in Philadelphia Chromosome-positive (Ph+) ALL of Young Adults (18-59 Years Old) (GRAAPH-2014)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Primary objective is to assess the non-inferiority of the experimental arm (arm B)&#xD;
      compared to the control arm (arm A) in terms of Major Molecular Response (MMolR) after the&#xD;
      4th cycle (MRD4) in patients aged 18-59 years old with de novo Philadelphia positive (Ph+)&#xD;
      acute lymphoblastic leukemia (ALL)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major Molecular Response (MMolR)</measure>
    <time_frame>4 cycles (4 months)</time_frame>
    <description>defined as a breakpoint cluster region (BCR)-Abelson (ABL) ratio &lt; 0.1% in the bone marrow sample of MRD4</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete remission after cycle 1</measure>
    <time_frame>day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of treatment- and transplantation-related mortality</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of relapse</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse free survival</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T315I mutation</measure>
    <time_frame>10 years</time_frame>
    <description>mutations will be assessed by Reverse transcription Quantitative Polymerase Chain Reaction (RQ-PCR) sequencing in case of progression or relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">265</enrollment>
  <condition>Philadelphia Chromosome Positive Adult Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>Intensive Arm (A)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4 cycles + 2 interphases +Hematopoietic Stem Cell Transplantation (SCT)&#xD;
+ Post-SCT Maintenance</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Light Arm (B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 cycles + 2 interphases +Hematopoietic Stem Cell Transplantation (SCT)&#xD;
+ Post-SCT Maintenance</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nilotinib</intervention_name>
    <description>400 mg/12h per os D1 to D28 cycles 1-4 300 mg/12h per os D1-D14 interphase</description>
    <arm_group_label>Intensive Arm (A)</arm_group_label>
    <arm_group_label>Light Arm (B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>1 g/m2 continuous Intravenous Infusion (CIV) D1 cycles 2 and 4 25 mg/m2 per os D1, D8 interphase</description>
    <arm_group_label>Intensive Arm (A)</arm_group_label>
    <arm_group_label>Light Arm (B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aracytine (Ara C)</intervention_name>
    <description>Age&lt;45 years: 3 mg/m2/12h D2, D3 cycles 2 and 4 Age&gt;=45 years: 1.5 mg/m2/12h D2, D3 cycles 2 and 4</description>
    <arm_group_label>Intensive Arm (A)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Granulocyte Colony-Stimulating Factor (G-CSF)</intervention_name>
    <description>5µg/kg/d (SC) D6 until neutrophils &gt; 1 G/L D15 cycles 1 and 3; D6 cycles 2 and 4</description>
    <arm_group_label>Intensive Arm (A)</arm_group_label>
    <arm_group_label>Light Arm (B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Depomedrol</intervention_name>
    <description>40 mg + methotrexate 15 mg + Aracytine (AraC) 40mg IT cycle 1: D1, D8, D15 IT cycles 2 and 4: D9 IT cycle 3: D1</description>
    <arm_group_label>Intensive Arm (A)</arm_group_label>
    <arm_group_label>Light Arm (B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>40 mg per os, D1-D2, D8-D9, D15-D16, D22-D23, cycles 1 and 3</description>
    <arm_group_label>Intensive Arm (A)</arm_group_label>
    <arm_group_label>Light Arm (B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>2 mg total dose IV, D1 D8 D15 D22 cycles 1 and 3</description>
    <arm_group_label>Intensive Arm (A)</arm_group_label>
    <arm_group_label>Light Arm (B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imatinib</intervention_name>
    <description>300 mg/12h per os in post-SCT maintenance therapy for during at least 2 years</description>
    <arm_group_label>Intensive Arm (A)</arm_group_label>
    <arm_group_label>Light Arm (B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>6 Mercaptopurine (6MP)</intervention_name>
    <description>60 mg/m2 per os, D1 to D14, interphase</description>
    <arm_group_label>Intensive Arm (A)</arm_group_label>
    <arm_group_label>Light Arm (B)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patient&#xD;
&#xD;
          1. Whose blood and bone marrow explorations have been completed before the steroids&#xD;
             prephase&#xD;
&#xD;
          2. Aged 18-59 years old with newly-diagnosed non previously treated Ph+ ALL according to&#xD;
             WHO 2008 criteria (confirmed diagnosis of the Philadelphia chromosome defined by the&#xD;
             reciprocal translocation of chromosomes 9 and 22, t(9;22) and/or presence of the&#xD;
             BCR-ABL molecular maker)&#xD;
&#xD;
          3. With ≥ 20% bone marrow blasts&#xD;
&#xD;
          4. With Eastern Cooperative Oncology Group (ECOG) Performans Status ≤ 3&#xD;
&#xD;
          5. With or without central nervous system (CNS) or testis involvement&#xD;
&#xD;
          6. Without evolving cancer (except basal cell carcinoma of the skin or &quot;in situ&quot;&#xD;
             carcinoma of the cervix) or its chemo- or radio-therapy should be finished at least&#xD;
             since 6 months.&#xD;
&#xD;
          7. Having received no previous treatment for this hematological disease (including IT&#xD;
             injection)&#xD;
&#xD;
          8. Having signed written informed consent&#xD;
&#xD;
          9. With efficient contraception for women of childbearing age (excluding estrogens and&#xD;
             IUD)&#xD;
&#xD;
         10. With health insurance coverage&#xD;
&#xD;
         11. Who have received (or being receiving) the recommended steroid prephase.&#xD;
&#xD;
        Note 1: Secondary ALL (antecedent of chemo- or radio-therapy) can be included Note 2: In&#xD;
        case of high vascular risk (see section &quot;study management&quot;) the patient will not be able to&#xD;
        receive nilotinib unless an ultra sound Doppler of the neck and lower limbs has been&#xD;
        performed during the pre-phase and treatment validated by the medical coordinators of the&#xD;
        protocol via the secretariat.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patient:&#xD;
&#xD;
          1. Previously treated with Tyrosine Kinase Inhibitor (TKI)&#xD;
&#xD;
          2. With another active malignancy&#xD;
&#xD;
          3. With general or visceral contra-indication to intensive therapy (except if considered&#xD;
             related to the ALL):&#xD;
&#xD;
               1. Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) &gt; 2.5 x&#xD;
                  upper limit of normal range (ULN)&#xD;
&#xD;
               2. Total bilirubin &gt; 1.5 x ULN&#xD;
&#xD;
               3. Creatinine &gt; 1.5 x ULN or creatinine clearance &lt;50 mL/mn&#xD;
&#xD;
               4. Serum amylase or lipase &gt; 1.5 x ULN or antecedents of acute pancreatitis&#xD;
&#xD;
          4. With heart failure, including at least one of the following criteria:&#xD;
&#xD;
               1. Left ventricular ejection fraction (LVEF) &lt;50% or below the lowest normal&#xD;
                  threshold, as determined by ECG or heart failure (NYHA grade III or IV)&#xD;
&#xD;
               2. Impossibility to measure the QT interval on ECG&#xD;
&#xD;
               3. Complete left bundle branch block&#xD;
&#xD;
               4. Pacemaker&#xD;
&#xD;
               5. Congenital long QT syndrome of known familial antecedents of long QT syndrome&#xD;
&#xD;
               6. Antecedents or current ventricular or atrial tachyarrhythmia, clinically&#xD;
                  significant&#xD;
&#xD;
               7. Baseline bradycardia (&lt;50 bpm) clinically significant&#xD;
&#xD;
               8. Corrected QT interval (QTc)&gt; 450 msec established on the mean of 3 baseline ECG&#xD;
&#xD;
               9. Antecedents of myocardial infarct in the past 6 months&#xD;
&#xD;
              10. Instable angor within the past 12 months&#xD;
&#xD;
              11. Any heart condition clinically significant (i.e. congestive heart failure,&#xD;
                  uncontrolled hypertension)&#xD;
&#xD;
          5. Active uncontrolled infection, any other concurrent disease deemed to interfere with&#xD;
             the conduct of the study as judged by the investigator&#xD;
&#xD;
          6. Severe evolving infection, or known HIV or Human T-Lymphotropic Virus type I (HTLV1)&#xD;
             seropositivity, or active infection by hepatitis B or C virus&#xD;
&#xD;
          7. Pregnant (beta-HCG) or nursing woman&#xD;
&#xD;
          8. Women of childbearing potential not willing to use an effective form of contraception&#xD;
             during participation in the study and at least three months thereafter. Patient not&#xD;
             willing to ensure not to beget a child during participation in the study and at least&#xD;
             three months thereafter.&#xD;
&#xD;
          9. Having received an investigational treatment or participation in another trial within&#xD;
             30 days prior to entering this study.&#xD;
&#xD;
         10. Not able to bear with the procedures or the frequency of visits planned in the trial.&#xD;
&#xD;
         11. Unable to consent, under tutelage or curators, or judiciary safeguard&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hervé Dombret, MDPhD</last_name>
    <phone>+33 (0)1 57 27 68 47</phone>
    <email>herve.dombret@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Véronique Lhéritier</last_name>
    <phone>+33(0)4 78 86 22 39</phone>
    <email>veronique.lheritier@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hopital Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hervé Dombret, MDPhD</last_name>
      <phone>+33 (0)1 57 27 68 47</phone>
      <email>herve.dombret@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>November 19, 2015</study_first_submitted>
  <study_first_submitted_qc>November 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2015</study_first_posted>
  <last_update_submitted>October 18, 2019</last_update_submitted>
  <last_update_submitted_qc>October 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Philadelphia Chromosome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Mercaptopurine</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

